Compare Dow Inc (DOW) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Gilead Sciences, Inc. — how do they compare? Dow Inc trades at $31.24 (market cap $22.58B), while Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 7.5× Dow Inc's market cap, and Dow Inc pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| DOW | GILD | |
|---|---|---|
Market Cap | $22.58B | $168.35B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $155.80 |
52-Week Low | $20.65 | $110.56 |
Enterprise Value | $38.27B | $191.42B |
Dividend Yield | 4.48% | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
